Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position
Express News | HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Galectin Therapeutics Analyst Ratings
Galectin Therapeutics 2Q Net $12.4M >GALT
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Express News | Galectin Therapeutics Inc- Qtrly Shr Loss $0.20
Express News | Galectin Therapeutics: Believes It Has Sufficient Cash to Fund Planned Operations, Research & Development Activities Through About May 15, 2025
Express News | Galectin Therapeutics: Navigate Trial on Track for Interim Top-Line Analysis in December 2024
Galectin Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Galectin Therapeutics Appoints Khurram Jamil, M.d. to Chief Medical Officer
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Largest Shareholders Are Retail Investors With 57% Ownership, Insiders Own 20%
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Galectin Therapeutics(GALT.US) Director Buys US$5,949.75 in Common Stock
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Express News | Galectin Therapeutics Inc: Navigate Trial Remains on Track for Interim Top-Line Readout Late in Q4 of 2024
Express News | As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Express News | Galectin Therapeutics Q1 Operating Income USD -9.648 Million
Express News | Galectin Therapeutics Q1 EPS USD -0.19